Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CTMX NASDAQ:PEPG NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.85+4.5%$2.01$0.98▼$4.46$610.92M0.469.58 million shs4.48 million shsCTMXCytomX Therapeutics$3.42-2.8%$3.46$1.72▼$8.21$599.06M2.085.34 million shs5.96 million shsPEPGPepGen$2.12-3.6%$1.74$1.01▼$7.80$152.17M1.881.02 million shs578,008 shsTECXTectonic Therapeutic$32.80+2.3%$31.07$14.39▼$39.53$618.90M3.21209,635 shs146,205 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+4.52%0.00%-7.50%-22.59%+40.15%CTMXCytomX Therapeutics-2.84%-6.56%+15.93%-25.81%+43.70%PEPGPepGen-3.64%-13.11%+18.44%+27.71%+60.61%TECXTectonic Therapeutic+2.28%-5.77%+9.26%+15.09%+49.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.85+4.5%$2.01$0.98▼$4.46$610.92M0.469.58 million shs4.48 million shsCTMXCytomX Therapeutics$3.42-2.8%$3.46$1.72▼$8.21$599.06M2.085.34 million shs5.96 million shsPEPGPepGen$2.12-3.6%$1.74$1.01▼$7.80$152.17M1.881.02 million shs578,008 shsTECXTectonic Therapeutic$32.80+2.3%$31.07$14.39▼$39.53$618.90M3.21209,635 shs146,205 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+4.52%0.00%-7.50%-22.59%+40.15%CTMXCytomX Therapeutics-2.84%-6.56%+15.93%-25.81%+43.70%PEPGPepGen-3.64%-13.11%+18.44%+27.71%+60.61%TECXTectonic Therapeutic+2.28%-5.77%+9.26%+15.09%+49.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52360.66% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10253.80% UpsidePEPGPepGen 2.71Moderate Buy$11.50442.45% UpsideTECXTectonic Therapeutic 2.75Moderate Buy$79.40142.07% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, ALLO, CTMX, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026TECXTectonic Therapeutic Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/16/2026PEPGPepGen Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.006/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026TECXTectonic Therapeutic Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.005/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACTMXCytomX Therapeutics$76.20M7.64N/AN/A$0.58 per share5.90PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)PEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)Latest PEPG, ALLO, CTMX, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026ALLOAllogene Therapeutics-$0.16N/AN/AN/A$0.00 millionN/A8/6/2026Q2 2026CTMXCytomX Therapeutics-$0.11N/AN/AN/A$12.39 millionN/A8/6/2026Q2 2026PEPGPepGen-$0.30N/AN/AN/AN/AN/A8/6/2026Q2 2026TECXTectonic Therapeutic-$1.3488N/AN/AN/AN/AN/A5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65CTMXCytomX TherapeuticsN/A10.3810.38PEPGPepGenN/A14.9814.98TECXTectonic TherapeuticN/A18.5118.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CTMXCytomX Therapeutics67.77%PEPGPepGen58.01%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CTMXCytomX Therapeutics3.80%PEPGPepGen1.30%TECXTectonic Therapeutic39.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.16 million299.60 millionOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionablePEPGPepGen3069.17 million68.27 millionNot OptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/APEPG, ALLO, CTMX, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Zacks Research2 hours ago | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Trading Up 6.3% - Time to Buy?July 17, 2026 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Stock Price Down 4.4% - Time to Sell?July 15, 2026 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Given Consensus Rating of "Buy" by BrokeragesJuly 13, 2026 | marketbeat.comTectonic Therapeutic IncJuly 2, 2026 | edition.cnn.comWhy Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%June 30, 2026 | aaii.comATectonic Therapeutic Completes Enrollment in Key TX45 TrialJune 10, 2026 | tipranks.comTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsJune 10, 2026 | globenewswire.comTectonic Therapeutic Inc TECXMay 31, 2026 | morningstar.comMRaymond James upgrades Tectonic Therapeutic (TECX)May 27, 2026 | msn.comTectonic Therapeutics: Currently In A Catalyst VacuumMay 19, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Insider Marcella Ruddy Sells 1,065 SharesMay 7, 2026 | insidertrades.comTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsApril 23, 2026 | globenewswire.comStifel initiates coverage of Tectonic Therapeutic (TECX) with buy recommendationApril 16, 2026 | msn.comTectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2April 16, 2026 | seekingalpha.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,000 Shares of StockApril 4, 2026 | insidertrades.comTectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLCMarch 15, 2026 | defenseworld.netDInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 6,262 Shares of StockMarch 10, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026PEPG, ALLO, CTMX, and TECX Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.85 +0.08 (+4.52%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$1.85 +0.00 (+0.22%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CytomX Therapeutics NASDAQ:CTMX$3.42 -0.10 (-2.84%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$3.40 -0.02 (-0.44%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.PepGen NASDAQ:PEPG$2.12 -0.08 (-3.64%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$2.10 -0.02 (-1.08%) As of 08:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Tectonic Therapeutic NASDAQ:TECX$32.80 +0.73 (+2.28%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$32.78 -0.02 (-0.05%) As of 07/21/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
